HYBRID EVENT: You can participate in person at Boston, Massachusetts, USA or Virtually from your home or work.
Risk and Benefit of New Therapies

Individualization of care with careful medication selection is increasingly recognized as one of the foundations of care for diabetes, which is not a disease of "one size fits all." The amount of time spent in a condition of hyperglycemia has long been known to raise the risk of complications. Hyperglycemia can leave a negative "metabolic memory" on cells of the vasculature and target organs, encouraging the development of difficulties in the future. Despite the necessity of meeting proper glycemic targets, there is still a gap between the goals specified and the goals achieved. Failure to commence or intensify treatment in a timely manner in persons whose health is expected to improve with this intensification is referred to as clinical inertia

Committee Members
Speaker at Diabetes, Metabolism and Endocrinology 2023 - Gretchen Holmes

Gretchen Holmes

Memorial Hospital at Gulfport, United States
Speaker at Diabetes, Metabolism and Endocrinology 2023 - Charles P Lambert PhD

Charles P Lambert PhD

Lambert Relentless R & D, LLC, United States
Speaker at Diabetes, Metabolism and Endocrinology 2023 - Alan J Stewart

Alan J Stewart

University of St. Andrews, United Kingdom
Diabetes 2023 Speakers
Speaker at Diabetes, Metabolism and Endocrinology 2023 - Maureen Groer

Maureen Groer

University of Tennessee Knoxville, United States
Speaker at Diabetes, Metabolism and Endocrinology 2023 - Madhu S Malo

Madhu S Malo

Diabetic Association of Bangladesh, United States
Speaker at Diabetes, Metabolism and Endocrinology 2023 - Sujith Rajan

Sujith Rajan

NYU Long Island School of Medicine, United States
Speaker at Diabetes, Metabolism and Endocrinology 2023 - Philippe P Pagni

Philippe P Pagni

Novo Nordisk Research Center, United States

Submit your abstract Today

Watsapp